How big is Aprea Therapeutics, Inc.?

As of Jun 18, Aprea Therapeutics, Inc. has a market capitalization of 9.85 million, with net sales of 1.28 million and a net profit of -14.07 million over the last four quarters. The company has shareholder's funds of 20.62 million and total assets of 23.98 million as of Dec 24.

Market Cap: As of Jun 18, Aprea Therapeutics, Inc. has a market capitalization of 9.85 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Aprea Therapeutics, Inc. reported net sales of 1.28 million and a net profit of -14.07 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company has shareholder's funds amounting to 20.62 million and total assets of 23.98 million.

What does Aprea Therapeutics, Inc. do?

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies that reactivate the mutant p53 tumor suppressor protein. As of March 2025, it has a market cap of $9.85 million, with no net sales and a net loss of $4 million.

Overview: <BR>Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate the mutant p53 tumor suppressor protein, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 9.85 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.14 <BR>Return on Equity: -83.51% <BR>Price to Book: 0.58<BR><BR>Contact Details: <BR>Address: 535 Boylston St, BOSTON MA: 02116-3720 <BR>Tel: 1 609 5104718 <BR>Fax: 1 302 6555049 <BR>Website: https://www.aprea.com/

Should I buy, sell or hold Aprea Therapeutics, Inc.?

Who are in the management team of Aprea Therapeutics, Inc.?

As of March 2022, Aprea Therapeutics, Inc.'s management team includes Mr. Christian Schade as Chairman, President, and CEO, with Mr. John Henneman as Lead Independent Director, alongside directors Michael Kelly, Dr. Fouad Namouni, Dr. Richard Peters, and Dr. Johan Christenson.

As of March 2022, the management team of Aprea Therapeutics, Inc. includes Mr. Christian Schade, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, Mr. John Henneman is the Lead Independent Director. The board also comprises directors such as Mr. Michael Kelly, Dr. Fouad Namouni, Dr. Richard Peters, and Dr. Johan Christenson, who is an Independent Director.

Is Aprea Therapeutics, Inc. overvalued or undervalued?

As of August 12, 2025, Aprea Therapeutics, Inc. is considered overvalued and has deteriorated from a risky to a non-qualifying investment grade, with a low Price to Book Value of 0.57, an EV to EBITDA ratio of 0.63, and a significant year-to-date return of -54.41%, underperforming the S&P 500.

As of 12 August 2025, the valuation grade for Aprea Therapeutics, Inc. has moved from risky to does not qualify, indicating a significant deterioration in its investment appeal. The company appears to be overvalued given its current metrics, particularly with a Price to Book Value of 0.57 and an EV to EBITDA ratio of 0.63, which suggest that the market is not valuing the company favorably compared to its peers. Additionally, the Return on Capital Employed (ROCE) is exceptionally high at 631.77%, but this is misleading due to the negative Return on Equity (ROE) of -83.51%.<BR><BR>In comparison to its peers, Aprea Therapeutics has a lower EV to EBITDA ratio than Cosmos Health, Inc. at -2.6396 and Lisata Therapeutics, Inc. at 0.1349, both of which are also classified as risky. The stock has underperformed significantly against the S&P 500, with a year-to-date return of -54.41% compared to the index's 12.22%, reinforcing the notion that Aprea Therapeutics is currently overvalued in the market.

Is Aprea Therapeutics, Inc. technically bullish or bearish?

As of September 9, 2025, Aprea Therapeutics, Inc. is in a bearish trend with weak strength, indicated by bearish signals from moving averages and Bollinger Bands, and has significantly underperformed the S&P 500 with a year-to-date return of -54.41%.

As of 9 September 2025, the technical trend for Aprea Therapeutics, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish with weak strength. Key indicators include a bearish signal from the daily moving averages and a bearish trend in both the weekly and monthly Bollinger Bands. The MACD shows a mildly bullish signal on the weekly but is bearish on the monthly, while the KST is mildly bullish weekly but bearish monthly. The Dow Theory indicates a mildly bearish stance on both weekly and monthly time frames. <BR><BR>In terms of performance, Aprea has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -54.41% compared to the S&P 500's 12.22%, and a one-year return of -47.55% versus 17.14%.